Table 3 IBD anti-inflammatory andimmunosuppressive treatment
From: Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease
| Â | n (%) |
|---|---|
None recorded | 7 (10.1%) |
Aminosalicylates | 29 (42%) |
 Mesalazine | 24 (34.8%) |
 Salazoprine | 5 (7.2%) |
Steroids | 44 (63.8%) |
 Methylprednisolone | 16 (23.2%) |
 Prednisolone | 42 (60.9%) |
 Budesonide | 2 (2.9%) |
Immunosuppressor | 41 (59.4%) |
 Azathioprine | 27 (39.1%) |
 6-Mercaptopurine | 2 (2.9%) |
 Methotrexate | 12 (17.4%) |
On-going immunosupressor at time of SIC review | 37/41 (90%) |
Biologic agent (infliximab) | 16 (23.2%) |
On-going biologic agent at time of SIC review | 14/16 (87.5%) |
Highest level of immunosuppression ever | |
 None/NSAID | 14 (20.3%) |
 Steroidimmunosuppressor | 38 (55.1%) |
 Biologic agent | 16 (23.2%) |